SCHEMBL6759384

SCHEMBL6759384

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1C(=O)N(C)C[C@@H]1OC(=O)O

nearest known ligand 0.76

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ACE P12821 13/20 0.76
LMNA P02545 2/20 0.56
ABCB11 O95342 2/20 0.54
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
USP2 O75604 1/20 0.53
CYP3A4 P08684 1/20 0.53
ALOX15 P16050 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
PDE3A Q14432 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7328410 0.91 ACE (0.73) ACE
Imidapril SCHEMBL11014327 0.87 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL3193644 0.87 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL7354516 0.87 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL34099 0.87 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL12894585 0.87 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL34098 0.87 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL6516062 0.87 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL22492310 0.87 ACE (1.00) ACELMNAABCB11MEN1KMT2A
Imidapril SCHEMBL683273 0.87 ACE (1.00) ACELMNAABCB11MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0274230-B1 USE OF 2-OXO-IMIDAZOLIDINE DERIVATIVES IN THE PROPHYLAXIS AND TREATMENT OF HEART FAILURE TANABE SEIYAKU CO., LTD. (JP) 1992-10-14 EP claimed
EP-1442743-A1 Medicament comprising alpha-lipoic acid, ambroxol and/or inhibitors of the angiotensin converting enzyme (ACE) for use in the treatment of neurodegenerative diseases KeyNeurotek AG (DE) 2004-08-04 EP disclosed